Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

456 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).
Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, Unnebrink K, Kaul M, Camez A; CHAMPION Study Investigators. Saurat JH, et al. Among authors: dubertret l. Br J Dermatol. 2008 Mar;158(3):558-66. doi: 10.1111/j.1365-2133.2007.08315.x. Epub 2007 Nov 28. Br J Dermatol. 2008. PMID: 18047523 Clinical Trial.
Intra-individual comparison of the cutaneous safety and efficacy of calcitriol 3 microg g(-1) ointment and calcipotriol 50 microg g(-1) ointment on chronic plaque psoriasis localized in facial, hairline, retroauricular or flexural areas.
Ortonne JP, Humbert P, Nicolas JF, Tsankov N, Tonev SD, Janin A, Czernielewski J, Lahfa M, Dubertret L. Ortonne JP, et al. Among authors: dubertret l. Br J Dermatol. 2003 Feb;148(2):326-33. doi: 10.1046/j.1365-2133.2003.05228.x. Br J Dermatol. 2003. PMID: 12588387 Clinical Trial.
CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.
Dubertret L, Sterry W, Bos JD, Chimenti S, Shumack S, Larsen CG, Shear NH, Papp KA; CLEAR Multinational Study Group. Dubertret L, et al. Br J Dermatol. 2006 Jul;155(1):170-81. doi: 10.1111/j.1365-2133.2006.07344.x. Br J Dermatol. 2006. PMID: 16792770 Clinical Trial.
Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study.
Viguier M, Pagès C, Aubin F, Delaporte E, Descamps V, Lok C, Beylot-Barry M, Séneschal J, Dubertret L, Morand JJ, Dréno B, Bachelez H; Groupe Français de Recherche sur le Psoriasis. Viguier M, et al. Among authors: dubertret l. Br J Dermatol. 2012 Aug;167(2):417-23. doi: 10.1111/j.1365-2133.2012.10940.x. Epub 2012 Jun 11. Br J Dermatol. 2012. PMID: 22413927
Recommendations for the use of etanercept in psoriasis: a European dermatology expert group consensus.
Boehncke WH, Brasie RA, Barker J, Chimenti S, Daudén E, de Rie M, Dubertret L, Giannetti A, Katsambas A, Kragballe K, Naeyaert JM, Ortonne JP, Peyrí J, Prinz JC, Saurat JH, Strohal R, van de Kerkhof P, Sterry W; European Dermatology Expert Group. Boehncke WH, et al. Among authors: dubertret l. J Eur Acad Dermatol Venereol. 2006 Sep;20(8):988-98. doi: 10.1111/j.1468-3083.2006.01707.x. J Eur Acad Dermatol Venereol. 2006. PMID: 16922950
European S3-guidelines on the systemic treatment of psoriasis vulgaris.
Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, Barker J, Bos JD, Burmester GR, Chimenti S, Dubertret L, Eberlein B, Erdmann R, Ferguson J, Girolomoni G, Gisondi P, Giunta A, Griffiths C, Hönigsmann H, Hussain M, Jobling R, Karvonen SL, Kemeny L, Kopp I, Leonardi C, Maccarone M, Menter A, Mrowietz U, Naldi L, Nijsten T, Ortonne JP, Orzechowski HD, Rantanen T, Reich K, Reytan N, Richards H, Thio HB, van de Kerkhof P, Rzany B. Pathirana D, et al. Among authors: dubertret l. J Eur Acad Dermatol Venereol. 2009 Oct;23 Suppl 2:1-70. doi: 10.1111/j.1468-3083.2009.03389.x. J Eur Acad Dermatol Venereol. 2009. PMID: 19712190
456 results